ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro

Leukemia

Volumn 25, Issue 9, 2011, Pages 1512-1516

  Amrein, L ^a   Rachid, Z ^b   Jean Claude, B ^b   Soulieres D ^c   Aloyz, R ^a   Panasci, L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; IMATINIB; PROTEIN P53; UNCLASSIFIED DRUG; ZRF4;

ARTICLE; CELL ASSAY; CELL ISOLATION; CELL LINE; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOCYTE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL PROLIFERATION; CHLORAMBUCIL; DNA DAMAGE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; TRIAZENES; TUMOR CELLS, CULTURED;

EID: 80052442962     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.110     Document Type: Article

References (8)

1. Sampath D, Plunkett W. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Curr Oncol Rep 2007; 9: 361-367. (Pubitemid 47377067)
2. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
3. Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 2009; 31(Part 2): 2290-2311.
4. Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 2004; 18: 409-414. (Pubitemid 38425852)
5. Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ et al. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol 2010; e-pub ahead of print December 2010, doi:10.1007/s00280-010-1530- 7.
6. Rachid Z, Katsoulas A, Williams C, Larroque AL, McNamee J, Jean-Claude BJ. Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorg Med Chem Lett 2007; 17: 4248-4253. (Pubitemid 47028602)
7. Rachid Z, Katsoulas A, Brahimi F, Jean-Claude BJ. Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase. Bioorg Med Chem Lett 2003; 3: 3297-3300. (Pubitemid 37093848)
8. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004; 16: 715-724. (Pubitemid 39586530)